

MICRUS ENDOVASCULAR CORP  
Form DEFA14A  
August 03, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934

Filed by the Registrant   
Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by §14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material §240.14a-12

Micrus Endovascular Corporation  
(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule

0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

---

---

---

On July 29, 2009, Micrus Endovascular Corporation, or the "Company", filed with the Securities and Exchange Commission the Company's definitive proxy statement, or the "Proxy Statement", relating to its 2009 Annual Meeting of Stockholders to be held on September 15, 2009. Although R. Michael Crompton is not a "Named Executive Officer" of the Company as of the end of our last completed fiscal year, in the Proxy Statement his name is mistakenly included in a table appearing under the caption "Cash-Based Incentive Compensation", a table appearing just before the caption "Grant of Plan-Based Awards in Last Fiscal Year" and footnote 6 of the table appearing under the caption "Potential Payments upon Termination or Change of Control". These tables, in each case, set forth certain information about our Named Executive Officers. However, despite the references to Mr. Crompton therein, he should not be considered a Named Executive Officer of the Company.

---

